Renal artery stenosis: If and when to intervene

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 2, 2016, Pages 144-151

  Textor, Stephen C ^a   McKusick, Michael M ^a  

^a MAYO CLINIC   (United States)

Author keywords

flash pulmonary edema; hypertension; ischemic nephropathy; renal artery stenosis; renovascular hypertension; stent

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; ENDOVASCULAR SURGERY; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; REVASCULARIZATION; REVIEW; VASCULAR SURGERY; ADAPTATION; ANGIOPLASTY; ANIMAL; ATHEROSCLEROSIS; COMPLICATION; INFLAMMATION; KIDNEY; PATHOPHYSIOLOGY; PATIENT SELECTION; RENAL ARTERY OBSTRUCTION; VASCULARIZATION;

ADAPTATION, PHYSIOLOGICAL; ANGIOPLASTY; ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; KIDNEY; PATIENT SELECTION; RENAL ARTERY OBSTRUCTION;

EID: 84957427727     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000202     Document Type: Review

References (34)

1. Mark PB, Schiffrin EL, Jennings GL, et al. Renovascular hypertension: to stent or not to stent? Hypertension 2014; 64:1165-1168.
2. Textor SC. Attending rounds: a patient with accelerated hypertension and an atrophic kidney. Clin J Am Soc Nephrol 2014; 9:1117-1123.
3. Herrmann SM, Saad A, Textor SC. Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). Nephrol Dial Transplant 2015; 30:366-375.
4. Textor SC. Renovascular hypertension: is there still a role for stent revascularization? Curr Opin Nephrol Hypertens 2013; 22:525-530.
5. Ritchie J, Green D, Chrysochou C, et al. High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization. Am J Kidney Dis 2014; 63:186-197.
6. Parikh SA, Shishehbor MH, Gray BH, et al. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv 2014; 84:1163-1171.
7. White CJ. The 'chicken little' of renal stent trials: the CORAL trial in perspective. JACC Cardiovasc Interv 2014; 7:111-113.
8. Kotliar C, Juncos L, Inserra F, et al. Local and systemic cellular immunity in early renal artery atherosclerosis. Clin J Am Soc Nephrol 2012; 7:224-230.
9. De Ciuceis C, Rossini C, La Boria E, et al. Immune mechanisms in hypertension. High Blood Press Cardiovasc Prev 2014; 21:227-234.
10. Webb TN, Ramratnam M, Evans RW, et al. Atherosclerotic renal artery stenosis as a cause for hypertension in an adolescent patient. Pediatr Nephrol 2014; 29:1457-1460.
11. Chrysant GS, Bates MC, Sullivan TM, et al. Proper patient selection yields significant and sustained reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: long-term results from the HERCULES trial. J Clin Hypertens 2014; 16:497-503.
12. De Bruyne B, Manoharan G, Pijls NHJ, et al. Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol 2006; 48:1851-1855.
13. Vaughan ED Jr. Curable renal hypertension: renin, marker or cause? Question answered. Am J Hypertens 2014; 27:1000-1003.
14. Mangiacapra F, Trana C, Sarno G, et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc Interv 2010; 3:537-542.
15. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. New Engl J Med 2014; 370:13-22.
16. Murphy TP, Cooper CJ, Cutlip DE, et al. Roll-in experience from the Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study. J Vasc Interv Radiol 2014; 25:511-520.
17. Ritchie J, Alderson HV, Kalra PA. Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials. Curr Opin Nephrol Hypertens 2014; 23:525-532.
18. Evans KL, Tuttle KR, Folt DA, et al. Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol 2014; 9:1199-1206.
19. Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 2008; 156:549-555.
20. Chrysochou C, Foley RN, Young JF, et al. Dispelling the myth: the use of reninangiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant 2012; 27:1403-1409.
21. Oderich GS, Greenberg RK, Farber M, et al. Results of the United States multicenter prospective study evaluating the Zenith fenestrated endovascular graft for treatment of juxtarenal abdominal aortic aneurysms. J Vasc Surg 2014; 60:1420-1428; e1421-1425.
22. Evans RG, Goddard D, Eppel GA, et al. Factors that render the kidney susceptible to tissue hypoxia in hypoxemia. Am J Physiol Regul Integr Comp Physiol 2011; 300:R931-R940.
23. Lerman LO, Textor SC. Gained in translation: protective paradigms for the poststenotic kidney. Hypertension 2015; 65:976-982.
24. Saad A, Herrmann SMS, Crane J, et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. Circ Cardiovasc Interv 2013; 6:428-435.
25. Rhee EP, Clish CB, Pierce KA, et al. Metabolomics of renal venous plasma from individuals with unilateral renal artery stenosis and essential hypertension. J Hypertens 2015; 33:836-842.
26. Textor SC, Lerman LO. Paradigm shifts in atherosclerotic renovascular disease: where are we now? J Am Soc Nephrol 2015; 26:2074-2080.
27. Lech M, Grobmayr R, Ryu M, et al. Macrophage phenotype controls long-term AKI outcomes: kidney regeneration versus atrophy. J Am Soc Nephrol 2014; 25:292-304.
28. Parekh DJ, Weinberg JM, Ercole B, et al. Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol 2013; 24:506-517.
29. Szeto HH, Liu S, Soong Y, et al. Improving mitochondrial bioenergetics under ischemic conditions increases warm ischemia tolerance in the kidney. Am J Physiol Renal Physiol 2015; 308:F11-F21.
30. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013; 24:1250-1261.
31. Eirin A, Ebrahimi B, Zhang X, et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res 2014; 103:461-472.
32. Eirin A, Li Z, Zhang X, et al. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension 2012; 60:1242-1249.
33. Eirin A, Zhang X, Zhu X-Y, et al. Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant 2014; 29:274-282.
34. Bruno RM, Daghini E, Versari D, et al. Predictive role of renal resistive index for clinical outcome after revascularization in hypertensive patients with atherosclerotic renal artery stenosis: a monocentric observational study. Cardiovasc Ultrasound 2014; 12:9.